Skip To Main Content
Julia Eve Olivieri on Muck Rack

Julia Eve Olivieri

As seen in: Nature, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Julia Eve

Contact Julia Eve, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Analysis of the coding transcriptome in NSCLC highlights variant-specific gene expression and signaling in CD74-ROS1 fusions

|
By Jasmine Vargas, Julia Eve Olivieri, Júlia Maria Olivieri, Georgios Pantouris
| Nature Verified
Abstract The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite its rare occurrence, CD74-ROS1 has a notable clinical value, with ROS1 inhibitors used as first-line therapeutics in precision medicine. Upon targeting the cancer with ROS1 tyrosine kinase inhibitors (TKIs), resistance occasionally emerges for reasons that are not well-understood.
Open in Who Shared Issue with article?

Analysis of the Coding Transcriptome in NSCLC Highlights Variant-Specific Gene Expression and Signaling in CD74-ROS1 Fusions

|
By Jasmine Vargas, Julia Eve Olivieri, Júlia Maria Olivieri, Georgios Pantouris
| preprints.org
This version is not peer-reviewed. Jasmine Vargas,Julia Olivieri  *,Georgios Pantouris  * Jasmine Vargas,Julia Olivieri  *,Georgios Pantouris  * Submitted: 05 November 2025 You are already at the latest version The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite the low occurrence, CD74-ROS1 has a notable clinical value serving as a therapeutic target when the primary treatment plan fails.
Open in Who Shared Issue with article?

Analysis of RNA processing directly from spatial transcriptomics data reveals previously unknown regulation

|
By Julia Eve Olivieri, Julia Salzman
| BioRxiv
New Results doi: https://doi.org/10.1101/2023.03.13.532412 Abstract Technical advances have led to an explosion in the amount of biological data available in recent years, especially in the field of RNA sequencing. Specifically, spatial transcriptomics (ST) datasets, which allow each RNA molecule to be mapped to the 2D location it originated from within a tissue, have become readily available.
Open in Who Shared Issue with article?
See all 4 articles